Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study-Reference-Cited by-同舟云学术

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

Published:2020-04 Issue:4 Volume:72 Page:613-626
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Harrison Stephen A.,Alkhouri Naim,Davison Beth A.,Sanyal Arun,Edwards Christopher,Colca Jerry R.^ORCID,Lee Bo Hyun,Loomba Rohit,Cusi Kenneth,Kolterman Orville^ORCID,Cotter Gad,Dittrich Howard C.^ORCID

Funder

Cirius Therapeutics, Inc

Publisher

Elsevier BV

Subject

Hepatology

Reference30 articles.

1. The global NAFLD epidemic;Loomba;Nat Rev Gastroenterol Hepatol,2013

2. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health;Rinella;Hepatology,2016

3. NAFLD and diabetes mellitus;Tilg;Nat Rev Gastroenterol Hepatol,2017

4. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes;Lomonaco;Diabetes Care,2016

5. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis;Anstee;Nat Rev Gastroenterol Hepatol,2013

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

3. Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review;Frontiers in Pharmacology;2024-09-03

4. Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?;Digestive and Liver Disease;2024-09

5. Manipulating mitochondrial pyruvate carrier function causes metabolic remodeling in corneal myofibroblasts that ameliorates fibrosis;Redox Biology;2024-09